Evaluating the Efficacy and Safety of Combining Ablative Fractional 1064-nm Picosecond Laser with Topical Rose Stem-Cell-Derived Exosomes for Hypertrophic Scar Treatment

Evaluating the Efficacy of Combining Fractional 1064-nm Picosecond Laser with Topical Rose Stem-Cell-Derived Exosomes for Hypertrophic Scar Treatment

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20260320004

Enrollment

Registered

2026-03-20

Start date

2026-02-27

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic scars at least 2 cm following trauma or surgery at least 6 months prior. Hypertrophic scars Picosecond laser Exosomes Rose stem cell derived exosomes Fractional Picosecond Laser LADD Laser Assisted Drug Delivery

Interventions

Ablative fractional 1064-nm picosecond followed by laser-assisted topical rose stem cell derived exosomes (RSCE) delivery in split scars design.,Ablative fractional 1064-nm picosecond laser mono-thera

Experimental Procedure/Surgery,Experimental Procedure/Surgery

Ablative fractional 1064-nm picosecond laser-assisted topical rose-derived stem cell exosomes (RSCE) delivery,Ablative fractional 1064-nm picosecond laser monotherapy

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Participants aged 20-60 years who present with hypertrophic scars more than 6 months, which were secondary to trauma or surgery. 2. Scar at least 2 cm in length. 3. Fitzpatrick skin type III-V 4. Capable of providing informed consent for operation and photographic investigation.

Exclusion criteria

Exclusion criteria: 1. Participants who take steroids, hormonal agents or Vitamin A derivatives within 6 months before. 2. Participants who received any scar treatment within 6 months prior enrollment. 3. Systemic comorbidity impairs tissue regeneration ie. Diabetes, Autoimmune. 4. Coagulopathy or current antiplatelet or anticoagulant therapy 5. Alcohol consumption or Tobacco use. 6. Pregnant or breastfeeding woman 7. Allergic to local anesthesia e.g. lidocaine or prilocaine

Design outcomes

Primary

Measure	Time frame
Scar Dimension i.e. width and height Every month x 5 Millilitre (mm) by medical caliper	—

Secondary

Measure	Time frame
Patient and Observer Scar Assessment Scale (POSAS) Every month x 5 POSAS Score,Vancouver Scar Scale (VSS) Every month x 5 VSS Score,Skin texture, Scar elevation, Melanin index, and Erythema index. Every month x 5 Antera 3D,Quality of Life Every month x 5 Dermatology Life Quality Index (DLQI)	—

Countries

Thailand

Contacts

Public ContactPongsatorn Wongwantanee

Dhurakij Pundit University

67130730@dpu.ac.th0812391818

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026